Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts | Nature Communications
Durable immunogenicity, adaptation to emerging variants, and low-dose efficacy of an AAV-based COVID-19 vaccine platform in macaques: Molecular Therapy
Lena Batoon on LinkedIn: Congratulations on this recent publication, Sema Hakki! Thanks for letting…
COVID-19 vaccine - Wikipedia
ALUMNUS Summer 2020 - Mississippi State University by MSSTATE - Issuu
Humoral immune responses associated with control of SARS-CoV-2 breakthrough infections in a vaccinated US military population - eBioMedicine
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial -
Genomic, immunological, and clinical analysis of COVID‐19 vaccine breakthrough infections in Beijing, China - Tian - 2022 - Journal of Medical Virology - Wiley Online Library
Keeping up with the COVID's—Could siRNA‐based antivirals be a part of the answer? - Forgham - 2022 - Exploration - Wiley Online Library
Vaccines | Free Full-Text | Association between COVID-19 Primary Vaccination and Severe Disease Caused by SARS-CoV-2 Delta Variant among Hospitalized Patients: A Belgian Retrospective Cohort Study
Frontiers | Viral Load in COVID-19 Patients: Implications for Prognosis and Vaccine Efficacy in the Context of Emerging SARS-CoV-2 Variants
Vaccines | Free Full-Text | The Delta and Omicron Variants of SARS-CoV-2: What We Know So Far
Beta RR-50
Are COVID-19 Vaccine Boosters Needed? The Science behind Boosters | Journal of Virology
Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2 - ScienceDirect
Viruses | Free Full-Text | SARS-CoV-2: Evolution and Emergence of New Viral Variants
Frontiers | Analysis of the Protective Efficacy of Approved COVID-19 Vaccines Against Various Mutants
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial -
Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts | Nature Communications
Molecular Ecology | Molecular Genetics Journal | Wiley Online Library
Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts | Nature Communications
Contextualizing Wastewater-Based surveillance in the COVID-19 vaccination era - ScienceDirect
Biomedicines | Free Full-Text | Immune Response and Molecular Mechanisms of Cardiovascular Adverse Effects of Spike Proteins from SARS-CoV-2 and mRNA Vaccines
Frontiers | Understanding spatiotemporal symptom onset risk of Omicron BA.1, BA.2 and hamster-related Delta AY.127
Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2 - ScienceDirect
